Clinical Trial Search

Primary: Total Severity Score (TSS): Percent Change From Baseline at Week 4 — -71.4; -66.7; -66.7; -57.1 Percent change — p=<0.01

Primary: Percent Change in ISGA (Investigator's Static Global Assessment) Score — 67.8 percent change

Primary: The Change of F-IGA From Baseline (BL) to wk 1 Will be the Primary Efficacy Variable. — -0.9; -0.6 units on a scale — p=.009

Primary: Number of Participants With Investigator Global Assessment of 0 or 1 at Week 4 — 20 Participants

Primary: Achievement of Investigator Global Assessment (IGA) Success at Week 8 — 104; 27 Participants — p=<0.0001

Primary: Efficacy Determined Using the Investigator's Global Assessment (IGA) - Adult — 2.1; 1.1 units on a scale — p=<0.001

Primary: Total Dandruff Severity Score (TDSS) — 28.6; 29.3; 26.7; 2.1 units on a scale

Primary: Achievement of Success on the Investigator Global Assessment (IGA) at Week 8 — 80; 58 percentage of participants — p=<0.0001

Primary: Number of Participants With ≥1 Adverse Event (AE) — 17; 23; 90; 3 Participants

Primary: SCORAD Change Score — 33.34 Change Score

Primary: Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment — 9; 0 Participants

Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change

Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale

Primary: Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success — 49; 41 Participants — p=0.2961

Primary: Percentage of Subjects Preffering Clobetasol Propionate Shampoo Better Than Comparator — 28.5; 31.6; 21.8 Percentage of participants — p=0.0003

Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…

Primary: Subjects With Investigator Global Assessment (IGA) Success (IGA of 0 or 1) at End of Treatment (Day 7 or 14). — 91.7; 96 percentage of participants — p=>0.05

Primary: Number of Participants With Any Adverse Event (AE) — 282 participants

Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001

Primary: Subject Satisfaction — 21; 14; 4; 0 Participants

Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…

Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants

Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance

Primary: Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis — -12.2; 9.3; -17.5 units on a scale — p=<0.05

Primary: Number of Participants With HPA Axis Suppression — 0; 2 Participants

Primary: Maintenance Phase: Time to First Relapse — 93.5; 56.8 days

Primary: Percentage of PLA Responders With Target Lesion Clear (PLA = 0) in Each Arm at Visit 8. — 22; 18; 1 Participants — p=<0.0001

Primary: Proportion of Subjects With All Target Lesions Cleared According to Physician Lesion Assessment Scale — 19; 0 Participants

Primary: Clinical Success in Patients With Moderate and Severe Scalp Psoriasis — 41; 43 Participants — p=0.4557

Primary: Relative Abundance of Staphylococcus Aureus Compared to Baseline — 0.106; 12.9 Relative abundance of S. aureus